What should you know about pembro tnbc?

Triple-negative breast cancer lacks three commonly measured receptors: oestrogen, progesterone and HER2. Because those receptors are not driving the treatment plan, hormone therapy and HER2-directed treatment are not the usual basis of care. Pembrolizumab works through the immune system and may be considered with chemotherapy or at another stage when the cancer's features and the treatment setting support it.

The word selected matters: the oncology team considers tumour testing, stage, previous treatment, health conditions and your preferences. A treatment name alone cannot show whether it is suitable for you or predict how your cancer will respond.

Ask which pathology and biomarker findings support pembrolizumab, whether it is planned before or after surgery, and how chemotherapy fits around it. Tell the team about autoimmune illness, organ problems, transplant history, steroid treatment, allergies and all medicines. Keep a record of fever, bowel changes, cough, breathlessness, rash, fatigue and other new symptoms.

Do not delay reporting symptoms because they seem mild. The team may need to assess an immune-related reaction, infection or a treatment effect before the next dose. PARP inhibitor therapy may be discussed in a different setting when inherited or tumour-related DNA-repair findings are relevant.

Contact your oncology team promptly for new breathlessness, persistent cough, diarrhoea, abdominal pain, yellowing of the skin, severe rash, marked weakness or changes in urine. Seek urgent help for severe breathing difficulty, fainting, confusion, seizure or rapidly worsening symptoms. Use the emergency contact instructions supplied by your treatment centre.

Ask why pembrolizumab is being considered, whether your tumour testing supports it, how it will be combined with chemotherapy, and how benefit and side effects will be monitored. Ask which symptoms require an immediate call, whether immunotherapy or PARP inhibitor therapy may be relevant later, and who coordinates your care.